Author

Henk‐André Kroon

Observed names: H.-A. Kroon, H.A. Kroon, Henk-Andre Kroon, Henk-André Kroon, Henk-André Kroon, Henk‐Andre Kroon

Institution: Annexon Biosciences (United States)

Observed institutions: Annexon Biosciences (United States), Alexion Pharmaceuticals (United States)

OpenAlex ID: A5052340658

Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria

2007 · Robert A. Brodsky, Neal S. Young, et al. · Blood · 685

Evaluation of the Morphological Effects of TDT 067 (Terbinafine in Transfersome) and Conventional Terbinafine on Dermatophyte Hyphae In Vitro and In Vivo

2012 · M. Ghannoum, N. Isham, et al. · Antimicrobial Agents and Chemotherapy · 32

PDF

Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome®) in patients with onychomycosis

2011 · R. Dominicus, C. Weidner, et al. · British Journal of Dermatology · 27

2007 · Gabrielle Meyers, Ilene Weitz, et al. · Blood · 23

Results From a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ANX005 , a C1q Inhibitor, in Patients With Guillain–Barré Syndrome

2025 · Quazi Deen Mohammad, Zhahirul Islam, et al. · Journal of the Peripheral Nervous System · 19

PDF

A Phase 2 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients with, or at Risk of, Manifest Huntington’s Disease (HD) (S32.009)

2023 · Rajeev Kumar, Daniel Claassen, et al. · Neurology · 18

Efficacy and Safety of Targeted Immunotherapy with ANX005 in Treating Guillain-Barré Syndrome: A Phase 3 Multicenter Study (PL5.006)

2025 · Henk-Andre Kroon, Zhahirul Islam, et al. · Neurology · 8

Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.

2006 · Robert A. Brodsky, Petra Muus, et al. · Blood · 5

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

2026 · Rajeev Kumar, Pinky Agarwal, et al. · Movement Disorders · 4

J08 A phase 2 open label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington’s disease (HD)

2022 · Rajeev Kumar, Daniel O Claassen, et al. · Journal of Neurology Neurosurgery & Psychiatry · 4

Inhibition of C1q, Initiator of the Classical Complement Cascade, by ANX005 for the Treatment of Guillain-Barré Syndrome: Results from a Phase 1b Study (763)

2020 · Zhahirul Islam, Nowshin Papri, et al. · Neurology · 4

2012 · Gabrielle Meyers, Ilene C. Weitz, et al. · F1000Research · 3

Plasma C4d levels correlate with treatment response and renal activity in proliferative lupus nephritis

2025 · Agneta Zickert, Caroline Grönwall, et al. · Lara D. Veeken · 1

PDF

P1552: a Phase 2, Open-label Study to Assess Safety, Tolerability, and Clinical Effect of Anx005 in Patients With Warm Autoimmune Hemolytic Anemia and Evidence of Complement Activation

2022 · U. Jaeger, C. Broome, et al. · HemaSphere · 1

Safety, Tolerability, and Clinical Pharmacology of ANX009, an Inhibitory Antibody Fab Fragment Against C1q, Administered Subcutaneously to Healthy Volunteers

2021 · Anita Grover, Jeffrey Teigler, et al. · Blood · 1

1.40P An open-label study evaluating tanruprubart in participants from North America and Europe with Guillain-Barré syndrome

2026 · Rafid Mustafa, Shafeeq Ladha, et al. · Neuromuscular Disorders

1.41P Tanruprubart in GBS: targeting early complement-associated inflammation conserved across the clinical spectrum and regions

2026 · Kazim Sheikh, Preeti Paliwal, et al. · Neuromuscular Disorders

1.36P A novel Guillain–Barré syndrome clinical progression scale to characterise the patient’s care journey: utilisation in a phase 3 trial of tanruprubart

2026 · Henk-André Kroon, Anton Nguyen, et al. · Neuromuscular Disorders

1.28P Baseline glycolipid IgG autoantibodies in GBS are prevalent and show cross-regional pattern concordance

2026 · Preeti Paliwal, Susan Halstead, et al. · Neuromuscular Disorders

Early Targeted C1q Inhibition With Tanruprubart Improves Functional Recovery in Guillain-Barré Syndrome: Results From a Phase Three Study (S21.002)

2026 · Henk-André Kroon, Zhahirul Islam, et al. · Neurology

An Open-label Study Evaluating the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Tanruprubart Single Dose in Participants From North America and Europe With Guillain-Barré Syndrome (P3-19.004)

2026 · Shafeeq Ladha, Rafid Mustafa, et al. · Neurology

219 Tanruprubart (ANX005) Targeted Therapy Reduces Ventilation Requirements in Guillain-Barré Syndrome

2025 · H.-A. Kroon, Q.D. Mohammad, et al. · Annals of Emergency Medicine

Beyond Binary: Biomarkers Reveal the Coexistence of Acute Motor Axonal Neuropathy (AMAN) and Acute Inflammatory Demyelinating Polyneuropathy (AIDP) in Guillain-Barré Syndrome (P9-11.001)

2024 · Henk-Andre Kroon, Kunal Kunani, et al. · Neurology

Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies

2023 · Edmund Chang, Julian Low, et al. · Journal of the American Society of Nephrology

Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show that the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis

2023 · Min Bao, Juan Lichauco, et al. · Journal of the American Society of Nephrology

Works count: 29

Citation count: 835

H-index: 7

I10-index: 6